Patents by Inventor Gregor Eichele
Gregor Eichele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9770444Abstract: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).Type: GrantFiled: December 17, 2014Date of Patent: September 26, 2017Assignee: MAX-PLANCK-GESELLSCHAFT-ZUR-FĂ–RDERUNG DER WISSENSCHAFTEN E.VInventors: Gregor Eichele, Henrik Oster, Silke Kiessling
-
Publication number: 20150105428Abstract: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).Type: ApplicationFiled: December 17, 2014Publication date: April 16, 2015Inventors: Gregor Eichele, Henrik Oster, Silke Kiessling
-
Patent number: 8946263Abstract: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).Type: GrantFiled: March 7, 2012Date of Patent: February 3, 2015Assignee: Max-Planck-Gesellchaft zur Forderung der Wissenschaften E.V.Inventors: Gregor Eichele, Henrik Oster, Silke Kiessling
-
Publication number: 20120230978Abstract: The present invention relates to a modulator of glucocorticoid biosynthesis, degradation and/or receptor activation for use in preventing or treating symptoms and/or diseases associated with jet lag. The compositions of the invention may be used as a lead compound for developing a drug for preventing or treating symptoms and/or diseases associated with jet lag. The invention relates to the discovery that administration of the modulator(s) to a subject results in a directional change of the time point of maximum amounts of glucocorticoids in the subject as compared to the time point of maximum amounts of glucocorticoids in a subject not treated with the modulator(s).Type: ApplicationFiled: March 7, 2012Publication date: September 13, 2012Applicant: Max-Planck-Gesellschaft-zur-Forderung der Wissenschaften e.V.Inventors: Gregor Eichele, Henrik Oster, Silke Kiessling
-
Publication number: 20060211768Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: ApplicationFiled: October 21, 2005Publication date: September 21, 2006Inventors: Ronald Evans, David Mangelsdorf, Richard Heyman, Marcus Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 7056954Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 10, 2003Date of Patent: June 6, 2006Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 6992108Abstract: A method for modulating lipid metabolism in a subject by administering 9-cis retinoic acid is presented. The 9-cis retinoic acid is more specific for the retinoid X receptor than is retinoic acid.Type: GrantFiled: June 7, 1995Date of Patent: January 31, 2006Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Publication number: 20040006144Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: ApplicationFiled: June 10, 2003Publication date: January 8, 2004Applicant: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 6623701Abstract: A specimen chamber (10) for the liquid treatment of at least one specimen (90) comprises a base plate (20) and a carrier plate (30), between which a gap-formed accommodation space is formed for the specimen, whereby the base plate and carrier plate (20, 30) are held together with a clamping device (60) in a frame arrangement (50), and in order to form the accommodation chamber are separated from one another by spacer elements (40), and the base plate (20) features, at an intake (11) on the side pointing towards the carrier plate (30), a tapering shape in order to form a wedge-shaped liquid reservoir (21).Type: GrantFiled: August 23, 2000Date of Patent: September 23, 2003Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Gregor Eichele, Uwe Herzig
-
Patent number: 6576676Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: July 9, 1999Date of Patent: June 10, 2003Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Publication number: 20030105166Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: ApplicationFiled: July 9, 1999Publication date: June 5, 2003Inventors: RONALD M. EVANS, DAVID J. MANGELSDORF, RICHARD A. HEYMAN, MARCUS F. BOEHM, GREGOR EICHELE, CHRISTINA THALLER
-
Patent number: 6506917Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 7, 1995Date of Patent: January 14, 2003Assignee: The Salk Institute for Biological StudiesInventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 6210923Abstract: The present invention provides DNA encoding a m-rigui2 protein selected from the group consisting of: (a) isolated DNA which encodes a m-rigui2 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a m-rigui2 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a m-rigui2 protein. Also provided is a vector capable of expressing the DNA adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. Further, a host cell transfected with the vector disclosed herein the vector expressing a m-rigui2 protein.Type: GrantFiled: December 24, 1998Date of Patent: April 3, 2001Assignee: Research Development FoundationInventors: Cheng-Chi Lee, Urs Albrecht, Gregor Eichele, Zhong-Sheng Sun
-
Patent number: 6190882Abstract: The present invention provides DNA encoding a RIGUI protein selected from the group consisting of: (a) isolated DNA which encodes a RIGUI protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a RIGUI protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a RIGUI protein. Also provided is a vector capable of expressing the DNA adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. Further, a host cell transfected with the vector disclosed herein the vector expressing a RIGUI protein.Type: GrantFiled: September 9, 1998Date of Patent: February 20, 2001Assignee: Research Development FoundationInventors: Cheng-Chi Lee, Urs Albrecht, Gregor Eichele, Zhong Sheng Sun
-
Patent number: 5968989Abstract: In accordance with the present invention, there are provided methods to modulate processes mediated by retinoid receptors, employing high affinity, high specificity ligands for such receptors. In one aspect of the present invention, there are provided ligands which are more selective for the retinoid X receptor than is retinoic acid (i.e., rexoids). In another aspect of the present invention, alternative ligands (other than retinoic acid) have been discovered which are capable of inducing retinoic acid receptor mediated processes. In yet another aspect, methods have been developed for the preparation of such retinoid receptor ligands from readily available compounds.Type: GrantFiled: June 7, 1995Date of Patent: October 19, 1999Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller
-
Patent number: 5932622Abstract: A method for modulating non-malignant skin related disorders in a subject has been demonstrated with 9-cis retinoic acid. Wrinkling, acne, keratinization, differentiation and proliferation disorders are treated by administration of 9-cis retinoic acid alone or in a pharmaceutically acceptable carrier to a subject in need thereof.Type: GrantFiled: June 7, 1995Date of Patent: August 3, 1999Assignees: The Salk Institute for Biological Studies, Baylor College of Medicine, Ligand Pharmaceuticals, Inc.Inventors: Ronald M. Evans, David J. Mangelsdorf, Richard A. Heyman, Marcus F. Boehm, Gregor Eichele, Christina Thaller